The Latest Analyst Ratings for ALX Oncology Holdings
Portfolio Pulse from Benzinga Insights
ALX Oncology Holdings (NASDAQ:ALXO) has received 10 bullish and no bearish ratings from analysts in the last quarter. The company's average 12-month price target is $18.55, a decrease of 29.81% from the previous average price target of $26.43.
October 04, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ALX Oncology Holdings has received positive analyst ratings, which could boost investor confidence. However, the decrease in the average price target could indicate a potential downside.
Analyst ratings can influence investor sentiment and thus the stock price. The positive ratings for ALXO are a good sign, but the decrease in the average price target could be a cause for concern, indicating that analysts may see less upside potential in the stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100